This inventor holds 2 USPTO granted patents and 3 published patent applications. Top assignee: Other. Active years: 2022-2023.
Company Filing History:
2 out of 834,350 Years Active: 2022-2023
Title: Paul N Durfee: Innovator in Cancer Treatment Technologies
Introduction
Paul N Durfee is a notable inventor based in Albuquerque, NM (US). He has made significant contributions to the field of cancer treatment through his innovative research and development of advanced therapeutic agents. With a focus on targeting bone cancer, his work has the potential to improve treatment outcomes for patients suffering from metastatic bone cancer.
Latest Patents
Paul N Durfee holds 2 patents that showcase his groundbreaking work. His latest patents include "Osteotropic nanoparticles for prevention or treatment of bone metastases," which involves protocells or nanoparticles designed to target bone tissue for delivering bioactive agents. These agents are crucial for the treatment and diagnosis of bone cancer, particularly metastatic bone cancer that often arises from primary cancers such as prostate, breast, lung, and ovarian cancers. Another significant patent is "Active targeting of cells by monosized protocells," which provides mesoporous silica nanoparticles (MSNPs) that exhibit cell binding specificity. This innovation allows for the targeted delivery of therapeutic agents to specific cancer cells, enhancing the effectiveness of treatments.
Career Highlights
Throughout his career, Paul N Durfee has demonstrated a commitment to advancing cancer treatment technologies. His innovative approaches have positioned him as a key figure in the field, contributing to the development of novel therapeutic methods that address critical medical challenges.
Collaborations
Paul has collaborated with esteemed colleagues such as Charles Jeffrey Brinker and Kimberly Butler. Their combined expertise has fostered an environment of innovation and discovery, leading to advancements in cancer treatment methodologies.
Conclusion
Paul N Durfee's contributions to cancer treatment through his innovative patents and collaborations highlight his dedication to improving patient outcomes. His work in developing targeted therapies represents a significant advancement in the fight against bone cancer.